121 related articles for article (PubMed ID: 3878262)
1. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus.
Eisenbarth GS; Srikanta S; Jackson R; Rabinowe S; Dolinar R; Aoki T; Morris MA
Diabetes Res; 1985 Nov; 2(6):271-6. PubMed ID: 3878262
[TBL] [Abstract][Full Text] [Related]
2. Long-term immunoregulatory effects of therapy with corticosteroids and anti-thymocyte globulin.
Schatz DA; Riley WJ; Silverstein JH; Barrett DJ
Immunopharmacol Immunotoxicol; 1989; 11(2-3):269-87. PubMed ID: 2695566
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus.
Silverstein J; Maclaren N; Riley W; Spillar R; Radjenovic D; Johnson S
N Engl J Med; 1988 Sep; 319(10):599-604. PubMed ID: 3045545
[TBL] [Abstract][Full Text] [Related]
4. Type I diabetes of man and the BB rat: monoclonal antibody-defined T-cell abnormalities.
Jackson RA; Eisenbarth GS
Diagn Immunol; 1983; 1(3):240-4. PubMed ID: 6333959
[TBL] [Abstract][Full Text] [Related]
5. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
Schatz D; Cuthbertson D; Atkinson M; Salzler MC; Winter W; Muir A; Silverstein J; Cook R; Maclaren N; She JX; Greenbaum C; Krischer J
Pediatr Diabetes; 2004 Jun; 5(2):72-9. PubMed ID: 15189492
[TBL] [Abstract][Full Text] [Related]
6. [Immuno- and regeneration therapy of recently diagnosed diabetes mellitus type I].
Huth E
Klin Padiatr; 1985; 197(2):75-84. PubMed ID: 3157826
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of replacing Minnesota antilymphocyte globulin with ATGAM.
Lum CT; Umen AJ; Kasiske B; Goerdt P; Heim-Duthoy KL; Andersen RC; Odland MD; Ney AL; Jacobs DM; Rao KV
Transplantation; 1995 Feb; 59(3):371-6. PubMed ID: 7871567
[TBL] [Abstract][Full Text] [Related]
8. T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe beta-cell lesions in phenotypic type 2 diabetes.
Goel A; Chiu H; Felton J; Palmer JP; Brooks-Worrell B
Diabetes; 2007 Aug; 56(8):2110-5. PubMed ID: 17473222
[TBL] [Abstract][Full Text] [Related]
9. Low dose poly I:C prevents diabetes in the diabetes prone BB rat.
Sobel DO; Goyal D; Ahvazi B; Yoon JW; Chung YH; Bagg A; Harlan DM
J Autoimmun; 1998 Aug; 11(4):343-52. PubMed ID: 9776712
[TBL] [Abstract][Full Text] [Related]
10. Treatment of severe aplastic anemia with antithymocyte globulin.
Rothmann SA; Streeter RR; Bukowski RM; Hewlett JS
Exp Hematol; 1982 Oct; 10(9):809-16. PubMed ID: 6983454
[TBL] [Abstract][Full Text] [Related]
11. Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study.
Pozzilli P; Manfrini S; Buzzetti R; Lampeter E; Leeuw ID; Iafusco D; Prisco M; Ionescu-Tirgoviste C; Kolouskovà S; Linn T; Ludvigsson J; Madàcsy L; Mrozikiewicz AS; Mrozikiewicz PM; Podar T; Vavrinec J; Vialettes B; Visalli N; Yilmaz T; Browne PD;
Diabetes Res Clin Pract; 2005 Jun; 68(3):258-64. PubMed ID: 15936469
[TBL] [Abstract][Full Text] [Related]
12. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
Päivärinta M; Tapanainen P; Veijola R
Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD38 autoantibodies: characterisation in new-onset type I diabetes and latent autoimmune diabetes of the adult (LADA) and comparison with other islet autoantibodies.
Mallone R; Ortolan E; Pinach S; Volante M; Zanone MM; Bruno G; Baj G; Lohmann T; Cavallo-Perin P; Malavasi F
Diabetologia; 2002 Dec; 45(12):1667-77. PubMed ID: 12488956
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients.
Mahlaoui N; Ouachée-Chardin M; de Saint Basile G; Neven B; Picard C; Blanche S; Fischer A
Pediatrics; 2007 Sep; 120(3):e622-8. PubMed ID: 17698967
[TBL] [Abstract][Full Text] [Related]
15. [Role of the steroids, SHBG, IGF-1, IGF BP-3 and growth hormone in glucose metabolism disorders during long-term treatment with low doses of glucocorticoids].
Vondra K; Hampl R; Nĕmcová D; Hill M; Hoza J; Kot'átková A; Stárka L; Vrbíková J; Zamrazil V
Cas Lek Cesk; 2002 Feb; 141(3):89-95. PubMed ID: 11925670
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
Johnson JL; Wolf SL; Kabadi UM
Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine trials in diabetes: updated results of the French experience.
Assan R; Feutren G; Sirmai J
Transplant Proc; 1988 Jun; 20(3 Suppl 4):178-83. PubMed ID: 3289203
[No Abstract] [Full Text] [Related]
18. White cells transfusion in recent onset type 1 diabetes.
Pozzilli P; Ghirlanda G; Manna R; Alfano G; Greco AV; Andreani D
Diabetes Res; 1986 Jun; 3(5):273-6. PubMed ID: 2943548
[TBL] [Abstract][Full Text] [Related]
19. Trial of mild immunosuppression by methisoprinol in acute onset diabetes mellitus: effects on rate and duration of remission.
Mirouze J; Rodier M; Richard JL; Lachkar H; Monnier L
Diabetes Res; 1986 Sep; 3(7):359-62. PubMed ID: 2430750
[TBL] [Abstract][Full Text] [Related]
20. Immunospecific therapy for type I diabetes mellitus.
Culler FL; O'Connor R; Kaufmann S; Jones KL; Roth JC
N Engl J Med; 1985 Sep; 313(11):695-6. PubMed ID: 3875034
[No Abstract] [Full Text] [Related]
[Next] [New Search]
